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Dl-sotalol is a specific beta-adrenergic blocking agent 
thl:\t markedly lengthens cardiac action potential dura•
tion. To determine whether d-sotalol, with little or no 
beta-blocking effect, also lengthens repolarization, stan•
dard microelectrode studies were used to determine the 
electrophysiologic properties of dl-sotalol and its stereo•
isomers in isolated rabbit and canine myocardial fibers. 
D- and l-sotalol produced concentration-dependent 
increases in action potential duration to 50% (APDso) 
and 90% (APD90) repolarization, respectively, and in the 
effective refractory period without changes in the max•
imal rate of rise of action potential. In rabbit sinoatrial 
node, d- and I-sotalol produced concentration-dependent 
increases in spontaneous sinus cycle length (29 and 35%, 
respectively) by lengthening tile action potential duration 
(by 58 and 55%) without effect on phase 4 depolariza-
Control of cardiac arrhythmias by the selective lengthening 
of the action potential duration is a growing concept in 
cardiac electropharmacology (1). In 1970 (2), it was found 
that in isolated cardiac muscle, the beta-adrenergic blocking 
agent, sotalol (MJl999), markedly and consistently length•
ened the action potential duration and, hence, the voltage•
dependent refractoriness. Such an effect was not accom•
panied by a change in either the upstroke velocity of phase 
zero of the action potential or membrane responsiveness 
From the Cardiology Section, Wadsworth Veterans Administration 
Hospital; the Department of Medicine, University of CalIfornia <It Los 
Angeles, School of Medicine, Los Angeles, California and the *Depart•
ment of Pediatrics, UniverSIty of New Mexico, School of Medlcme, Al•
buquerque, New Mexico. This study was supported m part by grants from 
the MedIcal Research Service of Veterans AdministratIOn, Washington, 
D.C., and by the Amencan Heart Association Greater Los Angeles Af•
filiate, Los Angeles, California. 
Manuscnpt receIved May 24, 1985; revised manuscnpt received August 
20, 1985, accepted September 3, 1985. 
Address for reprints: Bramah N. Smgh, MD. Cardiology SectIOn. 
6911111E, Wadsworth Veterans Administration Hospital, Wilshire/ 
Sawtelle Boulevards, Los Angeles. California 90073. 
© 1986 by the Amencan College of Cardiology 
tion. At the highest concentration (27.2 Itg/ml), d- and 
l-sot3101 prolonged APD90 (by 38 an" 54%, respectively, 
in Purkinje fibers and by 32 and 34% in ventricular 
muscle) and effective refractory period (by 49 and 49% 
in Purkinje fibers and 29 and 40% in ventricular mus•
cle). The effects of the two isomers wer~ not significantly 
different. At the middle concentration (Z.7 !,g/ml), 
d-sotalol, unlike I-sotalol, had no beta-adrenergic 
blocking effect, but the elfctrophysiologic effects of 
dl-, d- and I-sotalol were indistinguishable. 
The data indicate that d-sotalol is equipotent with 
I-sotalol in lengthening the action potential dqration and 
effective refractory period in cardiac muscle, an action 
unrelated to adrenergic antagonism or pharmacokinetic 
differences between the stereoisomers. 
(J Am Coil CardiaI1986;7:1l6-25) 
(2,3). In humans, intravenously administered sotalol has 
been found to increase the QTc interval on the electrocar•
diogram and to increase the effective refractory period of 
the atria, ventricles, atrioventricular (A V) node and acces•
sory tracts in the heart (4-6). Furthermore, intravenous so•
talol prolongs the duration of the monophasic action poten•
tials recorded by suction electrodes (7-9). Although the 
lengthening of the action potential duration does not appear 
to be an electrophysiologic correlate of beta-adrenergic 
blockade (10), long-term treatment of rabbits has been re•
ported (II) to prolong repolarization in the atria. 
The bulk of the reported experimental and clinical studies 
dealing with the electrophysiologic effects of sotalol have 
used the racemic mixture of the compound. It is not certain 
whether the electrophysiologic and antiarrhythmic proper•
ties of the levorotatory and dextrorotatory isomers of sotalol 
are identical. It is known, however, that the dextroisomer 
is largely devoid of beta-adrenoceptor blocking activity 
(12,13). The purpose of the present study was to c/etermine 
the comparative electrophysiologic profile of the two stereo•
isomers of sotalol relative to their beta-adrenergic block-
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ing potencies and the properties of the racemic compound 
in isolated cardiac muscle from the rabbit and dog, 
Methods 
Experimental preparations. New Zealand white male 
rabbits (weighing 2,0 to 3 0 kg) were used for studies of 
the sinoatrial (SA) node and atrial myocardium, The rabbits 
were anesthetized with sodium pentobarbital (30 mglkg body 
weight, intravenously), and the heart was rapidly removed 
and dissected in oxygenated Tyrode's solution, Atria in•
cluding the SA node were mounted, with the endocardial 
surface facing up in a tissue bath (10 ml in volume), 
Adult mongrel dogs of either ~ex (weighing 15 to 25 kg) 
were used for studies on Purkinje fibers and ventricular 
myocardium, After anesthesia with sodium pentobarbital 
(30 mg/kg, intravenomly), the heart was rapidly removed 
through a left lateral thoracotomy. Further dissection re•
sulted in preparations that included a right ventricular pap•
illary muscle and a portion of the endocardial right ven•
tricular free wall with the intervening false tendon~ attached 
Only the proximal and distal segments of the muscle were 
pinned to the tissue bath, leaving the Purkinje fibers undI~ 
turbed and entirely ~urrounded by the ~uperfus11lg media 
All preparations were superfused with Tyrode'~ solution 
(7,5 to 15 mllmin) at 36.0 ± O.soc. The composition of 
Tyrode's solution was as follows (mM), NaCI. 13U: KCI. 
40; CaCl2 , l:8~ MgSO~, 0.5: Na2 HPO~, 1.8: NaHU,J;, 
18,0; and glucose, 5 5, Tyrode's solution was bubbled with 
gas containing 95(K oxygen and 5o/c carbon dioxide, and 1t~ 
pH was maintained at 7.40 :+: 0 02, 
Electrophysiologic recordings. Sinoatrial node prepa 
rations (rabbit) were allowed to beat spontaneou~ly while 
atrial and ventricular muscle preparations (dog) wae dec 
trically stimulated through bipolar silver wire electrode at 
2 5 and 1 Hz, respectively Rectangular pulses of twice 
threshold voltage (2 m~ in duration) were delivaed by a 
Gras~ S88 stimulator with isolated output Action potentiab 
were recorded through glass microelectrodes t1lIed with 3M 
KCl (tip resistance 15 to 3Un) Signals were amplified with 
a microelectrode amplifier (Mentor N,950) with capa(;ity 
compensation, and were displayed on an oscilloscope (Tek 
tronics R564B) and photographed on Polaroid film The 
maximal upstroke velocity of pha~e zero of the action po•
tential (V md') was obtained by electronic differentiation, 
After an equilibration period of 60 to 90 minutes, action 
potentials were recorded in the standard manner Sinoatrial 
node action potentials were recorded continuously during 
spontaneous rhythm from the same cells throughout the 
experiments. Rabbit atrial action potentials were recorded 
from the crista terminalis whIle the adjacent myocardium 
was paced at 2,5 Hz. Canine ventricular preparations were 
paced contIlluously at I Hz, Purkinje fiber actIOn potentiab 
were recorded from free-runnIllg bundles ncar theIr insertIOn 
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mto the right papillary muscle, the area of maximal action 
potential amplitude and duration, Ventricular action poten•
tials were obtained from the papillary mUi>cles at a site near 
the stimulation electrode. Effective refractory periods were 
determined by introducing extrastimuli having progressively 
shorter coupling intervals after every 8 to 10 basic paced 
beats, The effective refractory period was determined as the 
shortest premature interval producing a response that de•
polarized beyond the zero potential line, 
Drug superfusion protocols. Test solutions of each of 
the three compounds (d-, 1- and dl-sotalol) were prepared 
by dissolving them in small quantities of Tyrode's solution, 
which were then added to separate reservoirs of oxygenated 
Tyrode's ~olutlon to obtain final concentrations of 10-6M 
(0,27 ILg/ml) to 10 4M (27 ILg/ml) , Control action poten•
tials were recorded after at lea~t 60 minutes of equilibration 
Multiple concentrations of the te~t drug were administered 
by the method of cumulati ve addition Repeat recordings 
were made after 30 minutes (for SA node) and 60 mmutes 
(for atria, ventricular muscle and Purkinje fibers) of super•
fusion at each drug concentration, 
Measurements and data analysis. Variable~ mea~ured 
from SA node action potentiab were: spontaneous sinus 
cycle length, maximal diastolic potential, action potential 
amplitude, thrci>hold potential of phase zero depolarizatioll, 
slope llf phase 4 depolarization, action potential duration at 
1U0(1r repolarization (APD) and maximal rate ot rise of 
phai>c lero (Vmax ). Actiun potentials. membrane re~tl1lg po•
tential. VllIax , action potential duration at 50% (APD,o) and 
9UO/C repolarization (APDljo) and effective refractory period 
were al~o measured from atria. Purkinje fibers and ventric•
ular muscle, 
Bccau~e ot the electrophy~iologlcally heterogeneous na•
ture of the SA node cell~, only data from those expenments 
in which a single SA node cell remained impaled by the 
microclectrode throughout the study are included for anal•
YSIS, To i>tudy the chronotropic beta-adrenergic blocking 
activities of the stereoisomers of sotalol. isoproterenol was 
superfused from 10 q to 10 - 4M before and m combination 
WIth d or l-~otalol of 10 5 and 10 ~M, respectively, using 
right atrial preparations with spontaneously firing SillUS nodes. 
Pharmacokinetic studies. Five female mongrel dogs 
(weIghing U~ 0 to 25,5 kg) were fasted ovcrnight, given 
morphine sulfate (0,5 mg/kg, intramuscularly) and after 15 
minutei>, mildly anesthetized with pentobarbital (20 mg/kg), 
They were given d-, 1- and dl-sotalol (3 mg/kg; 30 mg/ml 
in aqueous solution) intravenously at 2 week intervals, 
Blood samples (5 ml each) were collected at 5. 10, 15 and 
30 minute~ and I, 1.5, 2, 4. 6. 8 and lO hours after drug 
administration for the detennination of ~erum levels 
Serum .IO[alol cOllcellfratiom were determined by a high 
performance liquid chromatographic method (\ 4) 'itandard•
Ized 111 our laboratory Serum concentration ver~us time 
l'urvc, for d-, 1- and dl-sotalol were analyzed by nonlinear 
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least squares fits of a sum of two exponentials using program 
BMDP3R (15). The individual model variables and standard 
errors for the data from each dog were used to estimate the 
experimental mean by a maximal likelihood estimation scheme 
(16). Beta-phase elimination half-life, mean residence time, 
apparent volume of distribution at steady state and total 
clearance were obtained from the model variables using 
conventional formulas (17). 
Statistical analysis. The data are presented as mean ± 
standard deviation unless otherwise stated. A two-way anal•
ysis of variance was used to determine the significance of 
differences between groups in relation to the electrophysi•
ologic effects of the two isomers and those of the racemic 
compound. The values are based on the individual averages 
of the data from each preparation. A probability value of 
less than 0.05 was considered statistically significant. 
Results 
Effects on action potentials. 1) Rabbit SA node. The 
effects of varying concentrations of d- and I-sotalol on action 
potential characteristics in sinoatrial (SA) node preparations 
are summarized in Table 1. Typical examples of original 
records are shown in Figure I. In rabbit SA node, d- and 
I-sotalol (10- 6 to W- 4M) caused a concentration-dependent 
increase in spontaneous sinus cycle length and action po•
tential duration at 100% repolarization. At the highest con•
centration, d- and I-sotalol increased sinus cycle length by 
29 and 34%, respectively, and action potential duration at 
100% depolarization by 58 and 55%. However, neither 
d- nor I-sotalol had effects on the action potential amplitude, 
the maximal diastolic potential or the slope of phase 4 de•
polarization. The maximal rate of rise of phase zero de•
polarization (V max) was unaltered by each drug in the range 
of the concentrations used. Corresponding values before and 
after each drug superfusion (0.27, 2.72 and 27.2 jLg/ml) 
were 8.1 ± 5.7,8.7 ± 6.5,8.3 ± 5.7 and 7.3 ± 6.0 Vis 
for d-sotalol (n = 6) and 6.2 ± 4.8, 9.0 ± 7.2, 6.9 ± 
4.8 and 6.0 ± 5.0 Vis for I-sotalol (n = 6). 
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Figure 1. Effects of increasing d-sotalol (left panel) and I-sotalol 
(right panel) concentrations on rabbit sinoatrial node action po•
tentials. The upper traces of each panel show the transmembrane 
action potential, and the lower traces represent the rate of rise of 
the action potential (V max) obtained by electronic differentiation. 
Note the concentration-related increases in sinus cycle length with 
each drug due to the lengthening of the action potential duration. 
2) Rabbit atria. The effects of d- and I-sotalol on action 
potential characteristics in atrial muscle preparations are 
summarized in Table 2. Both d- and I-sotalol prolonged the 
action potential duration at 90% repolarization (APD90) and 
the effective refractory period in a concentration-dependent 
manner. However, only at the highest concentration were 
these changes significant. Neither d- nor l-sotalol had effects 
Table 1. Effects of d-Sotalol (n = 6) and I-Sotalol (n = 6) on Action Potential Variables of Rabbit Sinoatrial Node 
Control I x JO- 6M I x JO- 5M I x JO- 4M 
SCL 0 473 ± 67 476 ± 58 498 ± 44 609 ± 38t 
(ms) L 432 ± 99 470 ± 67 495 ± 67* 581 ± 67t 
APA 0 75 ± 15 75 ± 16 75 ± 16 72 ± 19 
(mV) L 70 ± II 72 ± II 71 ± II 66 ± 9 
MOP 0 66 ± 8 67 ± II 69 ± 11 66 ± II 
(-mV) L 66 ± 5 67 ± 6 66 ± 6 61 ± 6 
Slope of phase 4 0 35 ± 12 33 ± 14 33 ± JO 26 ± 6 
(mV/s) L 43 ± 16 43 ± 17 35 ± 12 31 ± 12 
APO 0 212 ± 35 216 ± 32 236 ± 34 336 ± 36t 
(ms) L 198 ± 31 206 ± 26 232 ± 22* 306 ± 49t 
*p < 0.05; tp < 0.01 versus control. Values are mean ± SO. APA = action potential amplitude; APO = action potentlal duration; 0 = d-sotalol; 
L = I-sotalol; MOP = maXImal diastolic potential; SCL = sinus cycle length; Slope of phase 4 = slope of dIastolic depolarization. 
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Table 2. Effects of d-Sotalol (n = 6) and l-Sotalol (n = 6) on Action Potential Variables of Rabbit Atrial Muscle 
Control I x lO- bM I x lO- sM I x 1O- 4M 
APA D 106 ± 3 99 ± 7 100 ± 7 101 ± 6 
(mV) L 101 ± 5 102 ± 7 104 ± 5 102 ± 4 
MRP D 80 ± 2 79 ± 5 78 ± 4 79 ± 4 
(-mV) L 80 ± 5 79 ± 4 80 ± 3 80 ± 2 
Vmax D 185 ± 33 162 ± 41 156 ± 36 183 ± 48 
(Vis) L 148 ± 40 158 ± 46 175 ± 43 148 ± 48 
APDso D 41 ± 7 41 ± 8 40 ± 5 45 ± 8 
(ms) L 35 ± 7 34 ± 10 38 ± 8 40 ± 10 
APD90 D 79 ± 16 76 ± 14 81 ± 12 92 :t 13* 
(ms) L 70 ± II 71 ± 13 76 ± 15 86 :t lit 
ERP D 69 ± 6 73 ± 12 75 ± 13 86:t lit 
(ms) L 68 ± 9 70 ± II 76 ± 13 89 ± 13t 
*p < 0.05; tp < 0.01 versus control. Values are mean ± SD. APDso = action potential duration at 50% repolarization; APD90 = action potential 
duration at 90% repolarizatton; ERP = effective refractory period; V max = rate of rise of phase zero depolarizatton; other abbreviations as in Table I. 
on action potential amplitude, membrane resting potential, 
\; max or APDso , even at the highest concentration. There 
was no statistically significant difference between d- and 
I-isomers in the electrophysiologic effects on the action po•
tentials of SA node or atrial muscle. 
3) Canine Purkinje fibers and ventricular muscle. The 
mean data demonstrating the effects of varying concentra•
tions of dl-, d- and I-sotalol on canine Purkinje fibers and 
ventricular muscle are presented in Tables 3 and 4. The 
representative original records are shown in Figures 2 and 
3, respectively. In neither Purkinje fibers nor ventricular 
muscles were action potential amplitude, membrane resting 
potential or \; max altered significantly in the range of each 
drug concentration used. The significant and consistent ef•
fects of each drug were on the repolarization phase of the 
action potential and on the effective refractory period in 
both Purkinje fibers and ventricular muscle. Dl-, d- and 
I-sotalol prolonged APD90 and the effective refractory period 
of Purkinje fibers and ventricular muscle as a function of 
drug concentration. An analysis of variance demonstrated 
that the three compounds did not differ significantly in their 
effects at any of the three concentrations examined. There 
was a trend for these variables to increase at a concentration 
of 1O- 6M. At lO-sM, the APD90 increased by 16% after 
dl-sotalol, 15% after d-sotalol and 19% after I-sotalol; the 
corresponding changes in the effective refractory period were 
24, 16 and 19%, respectively. In the case of ventricular 
muscle, the APD90 after dl-, d- and I-sotalol increased by 
21, 14 and 20%, respectively, while the effective refractory 
period lengthened by 19, 14 and 21 %. At the highest con•
centration of each drug, dl-, d- and I-sotalol prolonged the 
AP090 by 44, 38 and 54%, respectively, and also the ef•
fective refractory period by 51, 49, and 49%, in Purkinje 
fibers. 01-, d- and I-sotalol prolonged the AP090 by 31, 32 
Table 3. Effects of dl- (n = 5), d- (n = 7) and l-Sotalol (n = 7) on Action Potential Variables of Canine Purkinje Fibers 
Control I x 1O- 6M I x lO- sM I x 1O- 4M 
APA DL 124 ± 2 124 ± 2 125 ± 2 120 ± 5 
(mV) D 126 ± 3 126 ± 2 124 ± 2 123 ± 3 
L 126 ± 4 126 ± 6 126 ± 5 125 ± 5 
MRP DL 92 ± 2 92 ± 3 92 ± 2 90 ± 4 
(mY) D 91 ± 2 92 ± I 91 ± I 90 ± 2 
L 92 ± 4 92 ± 3 92 ± 3 92 ± 2 
V max DL 467 ± 39 453 ± 18 453 ± 20 453 ± 71 
(Vis) D 496 ± 28 489 ± 24 485 ± 14 463 ± 55 
L 478 ± 30 488 ± 96 482 ± 67 476 ± 67 
APDso DL 286 ± 12 291 ± 8 338 ± 15t 390 ± 58t 
(ms) D 289 ± 46 290 ± 45 314 ± 47t 368 ± 22t 
L 251 ± 30 273 ± 37* 305 ± 37t 369 ± 43t 
APD90 DL 348 ± 10 355 ± 4 403 ± 1St 500 :t 38t 
(ms) D 353 ± 51 361 ± 47 406 ± 48t 486 :t 36t 
L 325 ± 39 348 ± 38* 386 ± 44t 500 :t 57t 
ERP DL 271 ± 17 289 :t 20 336 :t 29t 410 :t 43t 
(ms) D 279 ± 37 291 ± 32 323 :t 34t 415 :t 34t 
L 268 :t 30 283 :t 33* 320 :t 39t 398 :t 38t 
*p < 0.05; tp < 0.01 versus control. Values are mean ± SD. DL = dl-sotalol; other abbreviations as in Tables I and 2. 
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Table 4. Effccts of dl- (n ~ 5), d- (n ~c 5) and I-Sotalol (n ~ 5) on Action Potcntial Variables of Can me Ventricular Muscle 
APA 
(mV) 
MRP 
(-mV) 
Vm,lJ( 
(Vis) 
APDso 
(mq 
APD90 
(ms) 
ERP 
(ms) 
DL 
D 
L 
')L 
D 
L 
DL 
D 
L 
DL 
D 
L 
DL 
D 
L 
DL 
D 
L 
Control 
105 ::Ie J 
105 ::Ie 3 
105 ::Ie 5 
83 ± 2 
85 ± 2 
80 ± 2 
203 ± 26 
174 ± 18 
202 ± 29 
180 ~ 20 
179 ± 8 
169 ± 23 
221 ± 21 
217 ± 7 
208 ± 19 
192 ± 14 
193 ± 7 
184 ± 10 
I ;( 10 "M 
106 + I 
106 ~ 4 
109 -±- 5 
85 " 2 
86 ± 3 
86 ± 3 
200 ± 25 
179 ::': 15 
205 :t 29 
193 ± 5 
192 ::': 10 
191 ::': 10 
233 ~ 6 
232 ± 10 
235 ± 13 
208 ± 17 
199 ± 12 
201 ± 12 
I x 10 'M 
109 + 2 
108 ± 3 
107 ± 2 
85 ± 3 
87 ± 2 
84 ± 4 
220 ± 39 
165 ::': 33 
202 ::': 19 
218 ::': 10* 
211 ± 9* 
147 ± 29* 
268 ± 6* 
247 ± 14* 
250 ± 20* 
229 ± 7t 
220 ± IS' 
223 ± 15* 
108 ~. 4 
106 ± .; 
108 ± 3 
gS + 4 
87 ± 2 
87 ± 2 
208 ::': 42 
153 ± 17 
219 ± 30 
237 ± 8t 
239 ± 19t 
220 ± II t 
289 ± lIt 
287 ± lit 
280 ± 19t 
246 ± 4t 
249 ± 19t 
256 ± 13t 
*p < 0.05; tp < 0.01 versus control Values are mean ::Ie SD. AbbreviatIOns a~ in Tables I and 2. 
and 34%, respectively. and the effective refractory period 
by 28. 29 and 40% in ventricular muscle. In all cases, the 
changes in the effective refractory period in Purkinje fibers 
and ventricular muscle paralleled those in the action poten•
tial duration. so that the ratios of effective refractory period 
to action potential duration were not influenced significantly 
by the stereoisomers of sotalol or by the racemic compound. 
Figure 4 presents the correlative data for d- and I-sotalol 
(10 - sM) with respect to the relation between the percent 
changes in the effective refractory period and APD9n in 
Purkinje fibers. A linear correlation is demonstrated for both 
compounds. Despite differences in the concentrations at 
which the drugs exerted statistically significant effects (com•
pared with control). data presented in Tables 3 and 4 delll•
onstrate that dl-. d- and I-sotalol had qualitatively as well 
as quantitatively similar electrophysiologic actions in Pur•
kinje fibers and ventricular muscle (Fig. 5). 
Chronotropic beta-adrenergic blocking activities of 
d- and I-sotalol. The dose-response curves to isoproterenol 
from concentrations of 10- 'l to 10 4M are shown in Figure 
6. Atrial action potentials were recorded from the crista 
terminalis near the SA node region to obtain spontaneous 
sinus frequency. At the middle concentration (10 'M). the 
dose-response curve under control conditions and that dur•
ing superfuslon with d-sotalol were nearly superimposable. 
In contrast. during superfusion with I-sotalol. the curve was 
shifted to the right by at least one log unit. consistent with 
a significant degree of beta-adrenoceptor blockade. At a 
concentration of 10 SM. d-sotalol had little or no effect on 
sinus automaticity enhanced by isoproterenol. At the higher 
concentration (10 4M). both d- and I-sotalol shifted the 
isoproterenol dose-re~ponse curve markedly to the right. 
I-sotalol being much more potent than d-sotalol 111 this regard. 
Serum elimination kinetics of dl·, I· and d-sotalol. 
The serum concentration profile as a function of time was 
determined after injection of do. 1- and dI-sotaIol in rabblt~, 
Figure 7 shows the elimination kinetics of dI-, d- and 1-
sotalol in a representative dog. The disappearance of la· 
cernic sotalol and its two optical isomers followed a biex•
ponential function. with a mean alpha-phase half-life of 12 
minute~ (range 3 to 44), 
Table 5 wmmarizes the pharmacokinetic variables after 
the intravenous administration of sotalol and its two ste·· 
reoisomCI5 Individual values for each of the variables var•
Ied over a wide range for all three forms of sotaloL The 
mean elimination half-life of 4.21 hours (range 2 8 to 5.4) 
for dl-~otalol wa~ ~imilar to that in another recent report 
(18), Thc mean re~idence time was 5.2i hours for dl-sotaIoL 
and the mean values for apparent volume of distribution at 
steady state and total clearance was 810 mllkg and 2.67 
mllmin per kg, respectively. Paired and unpaired tests and 
one- and two-way analyses of variance did not shuw any 
significant differences (all p > 0.2) among dl-. d- and 
l-sotaIol in any of the phannacokinetic variables. 
Discussion 
Our studle~ in isolated cardiac muscle from rabbit and 
dog heart~ have clearly established that the stereoisomers 
of sotalol exerted nearly Identical dectrophysiologic effect!'> 
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Figure 2. Effects of increasing d- (left) and I-sotalol (right) con•
centrations on the canine Purkinje fiber action potentials. The 
upper traces in each panel indicate zero potential, the middle 
traces represent the transmembrane potentials at a different time 
scale and the lower traces represent the differentiated rate of rise 
of phase zero of the action potential (V max). Voltage and time 
calibrations are the same for each panel. The time course of the 
action potentials has been displayed at two sweep velocities. Note 
the concentration-related increases in the action potential duration, 
but no reduction in V max with each drug. 
on a molar basis. For example, at a concentration (10-5M) 
at which d-sotalol had negligible beta-adrenergic blocking 
activity, there were no statistically significant differences 
between the effects of d- and l-sotalol on the action potential 
duration at 90% repolarization, in either Purkinje fibers (15 
versus 19%) or ventricular muscle (14 versus 20%). Sim•
ilarly, at this drug concentration, the changes in the effective 
refractory period in the Purkinje fibers (16 versus 19%) and 
ventricular muscle (14 versus 21 %) did not suffer signifi•
candy. In the atria, although the changes induced by the 
two isomers were less striking, the electrophysiologic ef•
fects of the two compounds were also quantitatively similar. 
Furthermore, in the Purkinje fibers and ventricular muscle, 
the overall effects of d- and l-sotalol were nearly identical 
to those of the racemic compound when tested at the same 
drug concentrations. Thus, our data further confirm that, 
unlike most other beta-adrenoreceptor blocking drugs (19), 
d1-sotalollengthens the effective refractory period of cardiac 
muscle by prolonging the action potential duration, with 
little or no effect on the maximal rate of rise of the action 
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Figure 3. Effects of increasing d- (left) and I-sotalol (right) con•
centrations on the action potential in canine ventricular muscle. 
Note the concentration-related increases in the action potential 
duration at 50% repolarization time but no reduction in the maximal 
rate of rise of the action potential with each drug. See legend for 
Figure 2 for details. 
potential. These findings are in accord with our previous 
observations (2) and those of others (3). 
Potential mechanisms of action potential duration 
lengthening by sotalol. Our current data on the overall 
actions of the stereoisomers of sotalol confirm and extend 
the observations of Carmeliet (20). At concentrations equal 
Figure 4. Relation between the increase In the effective refractory 
period (6ERP) and the increase in the action potential duration at 
90% repolarization time (6APD90) at 1O- 5M concentration of 
d-sotalol (left panel) and I-sotalol (right panel). The values shown 
are expressed as percent changes from baseline. The regression 
analysis was done by the method of least-squares fit. There is a 
highly significant correlation between the magnitude of alterations 
in the effective refractory period and that in the action potential 
duration. The data thus indicate that the effect of the two isomers 
is on the voltage-dependent refractoriness in cardiac muscle. 
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Figure 5. The mean changes in the action potential duration at 
90% repolarization time (ADP9Q) and the effective refractory period 
(ERP) in Purkinje fibers (a) and ventricular muscle (b) at 1O- 5M 
(left) and 1O- 4M (right) concentrations of dl-, d- and I-sotalol. 
It is evident that despite the differences in the concentrations at 
which the drugs exerted statistically significant effects (compared 
with control), there is no statistically significant difference in the 
percent changes among the three drugs when examined by an 
analysis of variance. 
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Figure 7. A semi logarithmic plot of the elimination kinetics of 
dl-sotalol (open circles). d-sotalol (open triangles) and I-sotalol 
(closed triangles) in one dog injected with 3 mg/kg body weight 
of each form of sotalol at 2 week intervals. The curves drawn are 
least-square fits to the observed data of a sum of two exponentials. 
There is no difference in the kinetics of elimination for the three 
compounds. 
HR(beats/min) 
A control Figure 6. Dose-response curve of rabbit sino•
atrial (SA) node after varying concentrations of 
isoproterenol. Ordinate, Spontaneous SA node 
firing rate (heart rate [HR] beats/min). Abscissa, 
Isoproterenol concentrations. Open triangles = 
control; open squares = d-sotaIol; closed squares 
= I-sotalol. Left, At the middle concentration 
(lO-5M) d-sotalol did not influence the control 
curve, but I-sotalol shifted it to a higher concen•
tration of isoproterenol. Right, At the highest con•
centration (lO-4M), both d- and I-sotalol shifted 
the dose-response curve to a higher concentration 
of isoproterenol. The antiadrenergic activity of 
I-sotalol was significantly (p < 0.01) greater than 
that of d-sotalol. At drug concentration of 10 - 5 M. 
d-sotalol is essentially devoid of beta-adrenergic 
blocking activity. 
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Table 5. Pharmacokinetic Variables of dl-, d- and I-Sotalol 
TI,e (h) 
MRT (h) 
Vd" (mlikg) 
CIt (mllmm per kg) 
dl-Sotalol 
4.21 :t 0.49 
5 21 :t 0 73 
810 :t 238 
2 67 :t 0.63 
d-Sotalol 
3.67 :t 0 72 
4.94 :t 0.85 
1,345 :t 381 
1.71 :t 0.67 
l-Sotalol 
3.90 :t I 43 
5.15 :t 2.11 
997 :t 95 
4.47 :t 2.10 
Data are mean :t SE from five dogs except for dl-sotalol (n '" 4). Individual vanables :t SE for each dog 
were used to obtain mean :t SE by maximal likelihood estimatIOn. One- and two-way analyses of variance 
showed that there were no slgmficant differences among the three groups with respect to any of the vanables. 
Cit'" total clearance; MRT '" mean residence time; TI~e '" mean eliminatIOn half-life, Vd" '" volume of 
distnbutlon at steady state. 
to or below 1O- 4M, the main electrophysiologic effects of 
sotalol and its isomers were to prolong the action potential 
duration. At higher concentrations, there were shortening 
of the action potential duration and a significant reduction 
in V max due to the inhibition of the tetrodotoxin-sensitive 
inward sodium current. Our data exclude the possibility that 
the observed lengthening of the action potential duration 
effected by sotalol is mediated through adrenergic antago•
nism since the dextroisomer, at a concentration (10 - 5 M) at 
which it had no significant beta-adrenergic blocking actions, 
was equipotent with the levoisomer in lengthening repolar•
ization and refractoriness. Thus, these changes must rep•
resent the intrinsic property of sotalol with respect to out•
ward repolarization currents. The voltage clamp studies of 
Carmeliet (20) have indicated that the lengthening of the 
action potential duration by sotalol may be due to a sub•
stantial reduction in the plateau of the outward potassium 
current in association with a small decrease in the back•
ground current. 
Consequences of action potential lengthening by so•
talol and its isomers. The overall electrophysiologic ef•
fects of sotalol and its isomers raise two theoretical possi•
bilities. First, the lengthening of repolarization will delay 
the inactivation of the slow calcium channel, which will 
tend to augment myocardial contractility. This is consonant 
with the findings of Kaumann and Olsson (21) who, indeed, 
reported a positive inotropic effect due to sotalol in cat 
papillary muscle in association with a markedly lengthened 
action potential duration. For the dextroisomer of sotalol, 
such an effect is likely to be more pronounced because it 
will not be attenuated by associated beta-receptor blockade. 
Second. the inhibition of the outward potassium currents by 
sotalol and its isomers will lengthen the refractory period. 
Our data, indicating that d-sotalol lengthens the effective 
refractory period to the same extent as I-sotalol or the ra•
cemic compound, constitute a valid assumption that the 
compound is likely to be a potent antiarrhythmic agent. A 
somewhat unexpected and unexplained observation in our 
study, however. was the fact that both isomers appeared to 
be equipotent in prolonging the cycle length of the spon•
taneously beating atria, there being no difference in their 
effect on the slope of phase 4 depolarization. 
Potential antiarrhythmic correlates of the electro•
physiologic effects of d- and I-sotalol. Numerous exper•
imental (2,22-28) and clinical (29-33) reports have docu•
mented a broad range of antiarrhythmic effects for dl-sotalol. 
Indeed, the spectrum of effects of the compound in arrhyth•
mias is wider than that of conventional beta-adrenergic 
blocking drugs (0). For example, unlike conventional beta•
blocking drugs, dl-sotalol has been found to be effective in 
lengthening the anterograde effective refractory period of 
the bypass tracts in the Wolff-Parkinson-White syndrome 
(4.5) and to prevent the reinduction of ventricular tachy•
cardia in experimental animals (27) and human subjects 
(34,35). These observations suggest that the additional an•
tiarrhythmic actions of dl-sotalol as compared with those of 
other beta-blocking drugs may be due to its propensity to 
lengthen repolarization and refractoriness in cardiac muscle. 
Although our data have clearly shown that the dextroisomer 
is equipotent with the levoisomer and the racemic compound 
in prolonging the effective refractory period, the data deal•
ing with the antiarrhythmic actions of d-sotalol are limited. 
However, Lynch et al. (24) recently found that 8 mg/kg 
intravenous cumulative doses of the 1- as well as the d•
isomer suppressed the induction of ventricular tachycardia 
in their conscious dog, ischemic model of sudden death in 
50% of the animals. At this dose, although only l-sotalol 
exerted an antiadrenergic effect such as lengthening of the 
PR interval of the surface electrocardiogram, both isomers 
produced equivalent increases of 15 to 20% in the ventricular 
effective refractory period. Our current in vitro electro•
physiologic data on the effects of the two isomers on the 
refractory period of cardiac muscle are in accord with these 
in vivo experimental findings and with the preliminary clin•
ical experience with intravenously administered d-sotalol in 
human beings (36, 37). 
Clinical implications. Our experimental findings clearly 
suggest that the dextroisomer of sotalol is as potent as the 
levoisomer or the racemic compound in lengthening the 
action potential duration and refractoriness of isolated car•
diac muscle. When considered in light of the limited pub•
lished data on the effects of the isomers in arrhythmias, 
these data indicate that d-sotalol may exert an antiarrhythmic 
spectrum similar to that of l-sotalol, but without the pro-
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pensity for suppressing adrenergic ally induced arrhythmias. 
However, the absence of beta-blocking activity with d-so•
talol as an antiarrhythmic agent carries a number of advan•
tages in certain clinical situations. First, unlike the racemic 
compound, d-sotalol is likely to be used with impunity in 
patients with diabetes, peripheral vascular disease and air•
way obstruction. Second, it has been shown by Brooks et 
al. (38) that the intravenous drug, unlike other beta-block•
ers, had little or no depressant effect on systemic hemo•
dynamics in patients with heart failure. It appears that the 
lengthening of the action potential duration induced by the 
drug may augment contractility, a phenomenon that has been 
demonstrated in isolated cardiac muscle (2,21). Such an 
effect may, in part, offset the depressant effect of beta•
blockade in a patient with cardiac decompensation, a feature 
that distinguishes sotalol from conventional beta-blocking 
drugs. It is known, however, that cardiac failure may be 
exacerbated in a small number of patients given dl-sotalol. 
The absence of beta-blocking activity in a d-isomer would 
obviate this possibility. 
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